Patients who don’t respond to treatments that use their own immune cells to destroy tumors, called tumor infiltrating lymphocytes, share changes in mechanisms that switch genes on or off in those cells, according to a new study.
Patients who don’t respond to treatments that use their own immune cells to destroy tumors, called tumor infiltrating lymphocytes, share changes in mechanisms that switch genes on or off in those cells, according to a new study.